Physician profile
Priya Angi
NPI 1639376361
$253.39
in general payments reported to CMS, 2019-2025
12 companies · $37.30 in 2025
The $37.30 reported for 2025 was less than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.82 · 2022: $22.60 · 2023: $67.38 · 2024: $32.29 · 2025: $37.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $53.46 | 2024-2025 | Rexulti |
| Abbott Laboratories | $36.84 | 2022-2023 | Freestyle Libre 3 |
| Allergan, INC. | $23.80 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.54 | 2023 | Rexulti |
| Mylan Specialty L.P. | $17.86 | 2019 | |
| Pfizer INC. | $16.53 | 2023 | |
| Lilly USA, LLC | $16.13 | 2024 | Amyvid |
| Abbvie INC. | $16.07 | 2023 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $13.52 | 2019 | |
| Acadia Pharmaceuticals INC | $13.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.85 | 2019 | |
| Novo Nordisk INC | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Angi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.